Filing Overview
This Form 6-K was filed by I-Mab (Nasdaq: IMAB), a foreign private issuer, for February 2024 and dated February 6, 2024. The filing identifies I-Mab as the registrant; the request metadata names Novabridge Biosciences, which should be verified.
Business and Management Update
I-Mab announced a change in its board and management composition. Joseph Skelton was appointed Chief Financial Officer effective February 5, 2024.
- Mr. Skelton succeeded Richard Yeh, who resigned from the Board and his executive positions with the Company.
- Mr. Skelton has nearly ten years of investment banking experience and has advised on transactions with aggregate value exceeding US$20 billion.
- His prior roles included Senior Vice President at Truist Securities covering biopharmaceuticals, as well as positions at Cantor Fitzgerald and Amneal Pharmaceuticals.
Financial Information
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Changes and Outlook
The material disclosed change is the replacement of the Chief Financial Officer and the resignation of the predecessor from the Board and executive positions. The filing provides no additional management outlook, operating guidance, risk disclosures, contingencies, or unusual financial items.
Key Facts to Verify
- Confirm that the filing relates to I-Mab rather than Novabridge Biosciences.
- Confirm the effective date of Joseph Skelton’s appointment: February 5, 2024.
- Review subsequent filings for any additional details regarding Richard Yeh’s resignation and the transition in financial leadership.
- Obtain I-Mab’s applicable periodic financial report for current financial performance and liquidity information.